Zebrafish Behavioral Profiling for Polypharmacology Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CNS drug discovery methods, particularly for psychiatric disorders like schizophrenia, face challenges due to high translational barriers and the lack of effective high-throughput behavioral screening tools, making it difficult to identify novel polypharmacological therapeutics.
Innovation Solution
A high-throughput zebrafish behavioral assay system is used to generate behavioral profiles in response to chemical compounds, allowing for the creation of a database to identify novel chemicals that mimic therapeutic agents, utilizing automated platforms and genetic or environmental perturbations to analyze phenotypic similarities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional target-based in vitro assays are used for CNS drug discovery, then the screening process is simplified and automated, but the ability to identify novel polypharmacological therapeutics for psychiatric disorders is significantly reduced
Solution Approach 1:
The patent creates behavioral profiles that copy and represent complex in vivo therapeutic effects in a simplified, quantifiable format. These behavioral profiles serve as digital representations of drug effects that can be stored, compared, and analyzed without requiring complex live animal testing for each compound evaluation.
Solution Approach 2:
The patent transforms complex behavioral outcomes into quantifiable parameters and numerical scores. By converting qualitative behavioral observations into measurable data points, the system enables high-throughput screening while preserving the complexity of polypharmacological effects.
2Productivity
If high-throughput behavioral screening is performed using traditional animal models, then comprehensive behavioral data can be collected, but the time, space, and financial resources required become prohibitive
Solution Approach 1:
The patent performs preliminary behavioral characterization to create reference profiles for known compounds. These pre-established profiles serve as templates that can be quickly compared against new compounds, eliminating the need to conduct full behavioral assays for every screening candidate.
Solution Approach 2:
The system creates digital copies of behavioral phenotypes that can be stored in databases and rapidly compared using computational methods. This eliminates the need to physically conduct repeated animal behavioral tests for compounds with similar expected profiles.
3Adaptability or versatility
If phenotype-based approaches are used to identify first-in-class compounds, then novel therapeutic mechanisms can be discovered, but the complexity of generating and analyzing behavioral profiles increases significantly
Solution Approach 1:
The patent divides complex behavioral phenotypes into discrete, measurable components or behavioral domains. Each domain can be independently scored and analyzed, allowing the system to handle complexity through modular assessment rather than as a monolithic evaluation.
Solution Approach 2:
The behavioral profile system serves multiple functions: it characterizes novel compounds, compares them to known therapeutics, identifies polypharmacological mechanisms, and prioritizes candidates for further testing. This multi-functional approach consolidates what would otherwise require multiple separate analytical systems.
Data Source
AI summary
Embodiments of the present invention provide materials and methods for performing phenotype-based chemical screens. Embodiments disclosed herein pertain to the use of a battery of high-throughput zebrafish behavioral assays to generate behavioral profiles. In accordance with these embodiments, responses to various chemical compounds with known and unknown biological functions can be used to generate behavioral profiles. Embodiments also involve generating behavioral profiles based on genetic mutations or environmental perturbations. Establishing databases of behavioral profiles facilitates identification of novel chemicals that phenocopy effects of therapeutic agents and/or that modulate genetic or environmental behavioral profiles, thereby providing a basis for not only assessing the properties of known chemical compounds but also for developing novel treatments for human diseases.